Vadadustat:After high
After high
2023年8月24日—Akebiaplanstoresubmititsapplicationforvadadustatforanemiaduetochronickidneydiseaseinadultpatientsondialysisbytheendofthe ...。其他文章還包含有:「Erythropoieticeffectsofvadadustatinpatientswithanemia...」、「FDAProvidesAkebiaTherapeuticsaPathForwardfor...」、「FDA拒絕批准貧血藥物Vadadustat,Akebia大規模裁員」、「VadadustatinPatientswithAnemiaandNon–Dialysis」、「Vafseo」、「Vafse...
查看更多 離開網站Erythropoietic effects of vadadustat in patients with anemia ...
https://pubmed.ncbi.nlm.nih.go
Thus, overall, vadadustat had beneficial effects on three aspects of erythropoiesis in patients with anemia associated with CKD: increased endogenous EPO ...
FDA Provides Akebia Therapeutics a Path Forward for ...
https://ir.akebia.com
Vadadustat is approved in Europe for the treatment of symptomatic anemia due to CKD in adult patients on chronic maintenance dialysis. In Japan ...
FDA 拒絕批准貧血藥物Vadadustat,Akebia 大規模裁員
https://geneonline.news
美國食品藥物管理局(FDA)因為安全問題近期拒絕批准美國生物製藥公司Akebia Therapeutics 用於治療慢性腎病引起的貧血藥物Vadadustat,因其增加了血栓
Vadadustat in Patients with Anemia and Non–Dialysis
https://www.nejm.org
Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, a class of drugs that stabilize HIF and stimulate ...
Vafseo
https://www.ema.europa.eu
The active substance in Vafseo, vadadustat, acts on an enzyme called hypoxia-inducible factor prolyl hydroxylase (HIF-PH). This stimulates the natural response ...
Vafseo, INN-vadadustat
https://www.ema.europa.eu
Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease. (CKD) in adults on chronic maintenance dialysis. Page 3. 3.
《FDA》不服慢性腎病貧血藥物Vadadustat藥證申請遭拒! ...
http://www.genetinfo.com
Vadadustat為一種口服缺氧誘導因子脯氨醯羥化酶抑制劑(HIF-PHI),旨在模擬人體對於低水平氧氣的反應,透過抑制HIF-PH可以促進紅血球增生並改善向組織的 ...
《FDA》安全問題! 美國FDA 拒絕批准Akebia 慢性腎病貧血藥 ...
http://www.genetinfo.com
據了解,在該試驗中,雖然使用vadadustat 的患者比使用對比藥物的患者出現了更多的血栓栓塞事件,但總體事件發生率是相同的─ 都是6.6 人/100 患者年( ...
《腎臟病》慢性腎病貧血候選藥物vadadustat 意外落馬
http://www.genetinfo.com
今年3 月30 日,美國FDA 以安全性問題,拒絕批准Akebia Therapeutics 原被相當被看好、用於治療慢性腎病貧血的低氧誘導因子脯胺醯羥化酶(HIF-PH) 抑制 ...